Blackstone bets $1.5B on Pfizer’s obesity drug

Coverage, in order

1. 1d ago
   
   first WSJ Health mainstream

   Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

   The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.

2. 16h ago
   Life Science Sweden Sweden indie

   Pfizer secures $1.5 billion to develop obesity drug
3. 15h ago
   Pharmaphorum UK indie

   Blackstone buys into Pfizer's GLP-1 drug development

   Blackstone buys into Pfizer's GLP-1 drug development Phil.Taylor Thu, 12/11/2026 - 10:33

4. 9h ago
   
   BioPharma Dive indie randomized trial

   Blackstone bets $1.5B on Pfizer’s obesity drug

   The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

5. 5h ago
   
   MedCity News indie study

   Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug Trials

   Blackstone Life Sciences is placing a bet on Pfizer’s berobenatide, a GLP-1 drug designed for monthly dosing. This GLP-1 drug comes from Metsera, which Pfizer acquired last year in a $10 billion deal.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.